Compass Therapeutics, Inc. financial data

Symbol
CMPX on Nasdaq
Location
80 Guest Street, Boston, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 11, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.2K % -42.5%
Debt-to-equity 15.1 % +190%
Return On Equity -53.1 % -71.9%
Return On Assets -46.1 % -57.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 138M shares +0.5%
Common Stock, Shares, Outstanding 138M shares +0.5%
Entity Public Float 98M USD -65.4%
Common Stock, Value, Issued 14K USD 0%
Weighted Average Number of Shares Outstanding, Basic 138M shares +0.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 16.4M USD +46.9%
General and Administrative Expense 16.7M USD +19.3%
Operating Income (Loss) -67.8M USD -23.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -16.6M USD -54.2%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -62M USD -31.3%
Earnings Per Share, Basic 0 USD/shares -22.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 22.9M USD +17.8%
Marketable Securities, Current 78.1M USD -38.4%
Cash, Cash Equivalents, and Short-term Investments 175M USD
Assets, Current 106M USD -30.8%
Property, Plant and Equipment, Net 131K USD -77.9%
Operating Lease, Right-of-Use Asset 9.8M USD +750%
Other Assets, Noncurrent 568K USD +77.5%
Assets 117M USD -25%
Accounts Payable, Current 2.6M USD +118%
Accrued Liabilities, Current 11M USD +52.1%
Liabilities, Current 13.9M USD +45.8%
Operating Lease, Liability, Noncurrent 9.63M USD
Liabilities 23.5M USD +147%
Accumulated Other Comprehensive Income (Loss), Net of Tax 208K USD
Retained Earnings (Accumulated Deficit) -401M USD -18.3%
Stockholders' Equity Attributable to Parent 93.2M USD -36.2%
Liabilities and Equity 117M USD -25%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -13.2M USD +4.9%
Net Cash Provided by (Used in) Financing Activities -815K USD -105%
Net Cash Provided by (Used in) Investing Activities 11.6M USD
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 138M shares +0.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.44M USD -340%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 23.4M USD +20.7%
Deferred Tax Assets, Gross 61.4M USD +38.7%
Operating Lease, Liability 9.9M USD +810%
Depreciation 100K USD -50%
Payments to Acquire Property, Plant, and Equipment 18K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -61.7M USD -31.8%
Lessee, Operating Lease, Liability, to be Paid 12.1M USD +979%
Property, Plant and Equipment, Gross 6.73M USD -6.04%
Operating Lease, Liability, Current 271K USD -75.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.2M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 1.59M USD +192%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.16M USD +7113%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.25M USD
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.29M USD
Operating Lease, Payments 1.3M USD 0%
Deferred Tax Assets, Net of Valuation Allowance 1.9M USD +291%
Share-based Payment Arrangement, Expense 9.74M USD +32.5%